Remicade (infliximab) antitrust $25M class action settlement

Update:

• The court granted this settlement final approval on March 15, 2023.
• Let Top Class Actions know when you receive a check in the comments section below or on our Settlements & Payouts Facebook group.

Johnson & Johnson and Janssen Biotech agreed to a $25 million class action lawsuit settlement to resolve claims they suppressed Remicade (infliximab) generic competitors.

The settlement benefits individuals and entities who indirectly purchased, paid for or provided reimbursement for some or all of the purchase price of Remicade (infliximab) between April 5, 2016, and Feb. 28, 2022.

Remicade (infliximab) is a biologic drug used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis, according to Rheumatology.org. The drug treats these conditions by stopping the body’s inflammation process.

In 2018, a consolidated class action lawsuit was filed against Johnson & Johnson and Janssen Biotech accusing the companies of suppressing competitors to Remicade ino order to secure a monopoly on the infliximab market. 

Plaintiffs say the two biomedical companies “worked to suppress competition and raise prices to purchases of [Remicade] by imposing a web of exclusionary contracts on both health insurers and healthcare providers” and “engaged in other anticompetitive conduct.” As a result of these actions, competitor products were allegedly barred from the market and the plaintiffs and other consumers were forced to pay more for Remicade than they would have in a competitive market.

The antitrust class action lawsuit contends that Johnson & Johnson and Janssen Biotech violated the federal Sherman Antitrust Act and Clayton Act, as well as state laws.

After four years of litigation, the defendants haven’t admitted any wrongdoing but agreed to pay $25 million to resolve these allegations.

Under the terms of the Remicade settlement, class members can collect a share of the settlement fund. 

Class members who paid more for Remicade during the class period will receive a larger share of the settlement fund. Class members may need to provide detailed purchase information to validate their claims. 

Exact payment amounts will vary but will be at least $25. Class members whose share of the settlement fund would be less than $25 will not receive a settlement payment.

If funds remain after the initial distribution, a second round of checks may be sent to class members. This second distribution will only occur if each class member would receive at least $10. If remaining funds do not warrant a second distribution, the money will be donated to the Crohn’s & Colitis Foundation or another non-profit approved by the court.

The deadline for exclusion and objection is Nov. 30, 2022. 

The final approval hearing for the Remicade settlement is scheduled for Feb. 27, 2023.

In order to receive benefits from the Remicade settlement, class members must submit a valid claim form by Nov. 30, 2022.

Who’s Eligible

The settlement benefits individuals and entities who indirectly purchased, paid for or provided reimbursement for some or all of the purchase price of Remicade (infliximab) between April 5, 2016, and Feb. 28, 2022.

Potential Award

Varies

Proof of Purchase

You will be asked to provide information or data proving that you are a member of the Settlement Class. You also may be asked to provide data showing your eligible purchases.

Claim Form

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

11/30/2022

Case Name

Remicade Antitrust Litigation, Case No. 2:17-cv-04326-KSM, in the District Court for the Eastern District of Pennsylvania

Final Hearing

02/27/2023

Settlement Website

RemicaseSettlement.com

Claims Administrator

Class Counsel

Alexandra S Bernay
ROBBINS GELLER RUDMAN & DOWD LLP

Defense Counsel

William F Cavanaugh
PATTERSON BELKNAP WEBB & TYLER LLP